Literature DB >> 21731514

Implementation in a large health system of a program to identify women at high risk for breast cancer.

William L Owens1, Thomas J Gallagher, Michael J Kincheloe, Victoria L Ruetten.   

Abstract

PURPOSE: PATIENTS AT HIGH RISK FOR DEVELOPING BREAST CANCER CAN BE IDENTIFIED USING A VALIDATED PREDICTIVE TOOL: the Gail model. Patients thus identified can undergo careful breast cancer screening and be considered for preventive measures, such as chemoprevention with tamoxifen or raloxifene. An organized health system can create a screening and high-risk intervention program for breast cancer and potentially save lives and resources. Multiple components of the health system must work together in a multidisciplinary manner to successfully implement such a program.
METHODS: Aurora Health Care is a large health system in Wisconsin. In 2007, a medical center within Aurora initiated a program to identify patients at high risk for developing breast cancer and intervene with screening and prevention. The program used the Gail model, which was administered to patients presenting for comprehensive physical examination at the women's center.
RESULTS: During the first year, 5,718 Gail model scores were calculated, and 15.2% of patients were deemed high risk. Most were counseled by their primary care providers, and few underwent screening with magnetic resonance imaging, genetics consultation, or chemoprevention. Primary care providers expressed concerns regarding the accuracy of the Gail model, the additional time necessary for patient counseling, how few patients underwent chemoprevention, and perceived medicolegal risk. The program was altered to address these concerns.
CONCLUSION: Success of a breast cancer risk and intervention program in a large health system is more likely if concerns of participating disciplines are acknowledged and addressed.

Entities:  

Year:  2011        PMID: 21731514      PMCID: PMC3051867          DOI: 10.1200/JOP.2010.000107

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  7 in total

1.  Chemoprevention of breast cancer: recommendations and rationale.

Authors: 
Journal:  Ann Intern Med       Date:  2002-07-02       Impact factor: 25.391

2.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  JAMA       Date:  2006-06-05       Impact factor: 56.272

3.  American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.

Authors:  Debbie Saslow; Carla Boetes; Wylie Burke; Steven Harms; Martin O Leach; Constance D Lehman; Elizabeth Morris; Etta Pisano; Mitchell Schnall; Stephen Sener; Robert A Smith; Ellen Warner; Martin Yaffe; Kimberly S Andrews; Christy A Russell
Journal:  CA Cancer J Clin       Date:  2007 Mar-Apr       Impact factor: 508.702

4.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.

Authors:  M H Gail; L A Brinton; D P Byar; D K Corle; S B Green; C Schairer; J J Mulvihill
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

5.  A breast cancer prediction model incorporating familial and personal risk factors.

Authors:  Jonathan Tyrer; Stephen W Duffy; Jack Cuzick
Journal:  Stat Med       Date:  2004-04-15       Impact factor: 2.373

6.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Authors:  B Fisher; J P Costantino; D L Wickerham; C K Redmond; M Kavanah; W M Cronin; V Vogel; A Robidoux; N Dimitrov; J Atkins; M Daly; S Wieand; E Tan-Chiu; L Ford; N Wolmark
Journal:  J Natl Cancer Inst       Date:  1998-09-16       Impact factor: 13.506

7.  Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme.

Authors:  E Amir; D G Evans; A Shenton; F Lalloo; A Moran; C Boggis; M Wilson; A Howell
Journal:  J Med Genet       Date:  2003-11       Impact factor: 6.318

  7 in total
  17 in total

1.  Genetic cancer risk assessment in general practice: systematic review of tools available, clinician attitudes, and patient outcomes.

Authors:  Flore Laforest; Pia Kirkegaard; Baljinder Mann; Adrian Edwards
Journal:  Br J Gen Pract       Date:  2018-12-03       Impact factor: 5.386

2.  Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.

Authors:  Laura L Reimers; Parijatham S Sivasubramanian; Dawn Hershman; Mary Beth Terry; Heather Greenlee; Julie Campbell; Kevin Kalinsky; Matthew Maurer; Ramona Jayasena; Rossy Sandoval; Maria Alvarez; Katherine D Crew
Journal:  Breast J       Date:  2015-04-16       Impact factor: 2.431

3.  Breast Cancer Risk Assessment Among Low-Income Women of Color in Primary Care: A Pilot Study.

Authors:  Emily E Anderson; Silvia Tejeda; Kimberly Childers; Melinda R Stolley; Richard B Warnecke; Kent F Hoskins
Journal:  J Oncol Pract       Date:  2015-06-02       Impact factor: 3.840

4.  Addressing barriers to uptake of breast cancer chemoprevention for patients and providers.

Authors:  Katherine D Crew
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

5.  Tamoxifen vs Raloxifene vs Exemestane for Chemoprevention.

Authors:  Laura Reimers; Katherine D Crew
Journal:  Curr Breast Cancer Rep       Date:  2012-09-01

6.  What Matters to Women When Making Decisions About Breast Cancer Chemoprevention?

Authors:  Kathryn A Martinez; Angela Fagerlin; Holly O Witteman; Christine Holmberg; Sarah T Hawley
Journal:  Patient       Date:  2016-04       Impact factor: 3.883

7.  Identifying Women at High Risk for Breast Cancer Using Data From the Electronic Health Record Compared With Self-Report.

Authors:  Xinyi Jiang; Julia E McGuinness; Margaret Sin; Thomas Silverman; Rita Kukafka; Katherine D Crew
Journal:  JCO Clin Cancer Inform       Date:  2019-03

8.  Acceptance and adherence to chemoprevention among women at increased risk of breast cancer.

Authors:  Richard G Roetzheim; Ji-Hyun Lee; William Fulp; Elizabeth Matos Gomez; Elissa Clayton; Sharon Tollin; Nazanin Khakpour; Christine Laronga; Marie Catherine Lee; John V Kiluk
Journal:  Breast       Date:  2014-12-06       Impact factor: 4.380

9.  Screening High-Risk Women Veterans for Breast Cancer.

Authors:  Yeun-Hee Anna Park; Alison Keller; Ta-Chueh Melody Hsu; Balmatee Bidassie; Vickie Venne; Douglas Hawley; Lori Hoffman-Högg; Bernadette Heron; Sarah Colonna; Anita Aggarwal
Journal:  Fed Pract       Date:  2021-05

10.  Organizational readiness to implement population-based screening and genetic service delivery for hereditary cancer prevention and control.

Authors:  Sarah Knerr; Kathleen M West; Frank A Angelo
Journal:  J Genet Couns       Date:  2020-01-22       Impact factor: 2.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.